Table 2.
Predicted outcomes with tafasitamab plus lenalidomide and lenalidomide monotherapy in the RE-MIND study. 45 .
| Predicted outcome | Tafasitamab plus lenalidomide cohort L-MIND regimen; n = 76 |
Lenalidomide monotherapy cohort RE-MIND; n = 76 |
Comparison (95% CI); p-value |
|---|---|---|---|
| ORR, % (95% CI) | 67.1 (55.4–77.5) | 34.2 (23.7–46.0) | OR = 3.9 (1.9–8.1); p < 0.0001 |
| CRR, % (95% CI) | 39.5 (28.4–51.4) | 13.2 (6.5–22.9) | – |
| Median OS, months a | NR | 9.4 | HR = 0.499 (0.317–0.785); p = 0.0026 |
| Median PFS, months b | 12.1 | 4.0 | HR = 0.463 (0.307–0.698); p = 0.0002 |
a
Median follow-up for OS = 21.5 months (tafasitamab + lenalidomide) and 20.9 months (lenalidomide).
b
Median follow-up for PFS = 19.7 months (tafasitamab + lenalidomide) and 12.6 months (lenalidomide).
CI, confidence interval; CRR, complete response rate; HR, hazard ratio; NR, not reached; OR, odds ratio; ORR, overall response rate; OS, overall survival; PFS, progression-free survival.